<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; launches</title>
	<atom:link href="http://www.tapanray.in/tag/launches/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>The Challenge of Holistic Value Creation With Pharma M&amp;A</title>
		<link>http://www.tapanray.in/the-challenge-of-holistic-value-creation-with-pharma-ma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-challenge-of-holistic-value-creation-with-pharma-ma</link>
		<comments>http://www.tapanray.in/the-challenge-of-holistic-value-creation-with-pharma-ma/#comments</comments>
		<pubDate>Mon, 19 Aug 2019 00:00:58 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[avant-garde]]></category>
		<category><![CDATA[Broader]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[cycle]]></category>
		<category><![CDATA[Disruptive]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[greater]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[launches]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[merger]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[possibilities]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[redefining]]></category>
		<category><![CDATA[takeovers]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[value-creation]]></category>
		<category><![CDATA[virtuous]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9675</guid>
		<description><![CDATA[Two mega deals, right at the dawn of 2019 gave a flying start to Merger &#38; Acquisition (M&#38;A) activities, in search of inorganic growth, by some large pharma companies. The two biggest ones are Bristol-Myers Squibb’s (BMS) USD 74 billion buyout of &#8230; <a href="http://www.tapanray.in/the-challenge-of-holistic-value-creation-with-pharma-ma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-challenge-of-holistic-value-creation-with-pharma-ma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Relevance Of Outliers In Pharma Sales Forecasting</title>
		<link>http://www.tapanray.in/relevance-of-outliers-in-pharma-sales-forecasting/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=relevance-of-outliers-in-pharma-sales-forecasting</link>
		<comments>http://www.tapanray.in/relevance-of-outliers-in-pharma-sales-forecasting/#comments</comments>
		<pubDate>Mon, 07 Aug 2017 00:00:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[accuracy]]></category>
		<category><![CDATA[analyzing]]></category>
		<category><![CDATA[downside]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[forecast]]></category>
		<category><![CDATA[forecasting]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[launches]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[outliers]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[upside]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8341</guid>
		<description><![CDATA[Just like any other predictions or forecasting &#8211; on a broader sense, pharma sales forecasts are also a tough and tedious task. Availability of many sophisticated state of the art digital software tools and techniques, notwithstanding. In an article, published &#8230; <a href="http://www.tapanray.in/relevance-of-outliers-in-pharma-sales-forecasting/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/relevance-of-outliers-in-pharma-sales-forecasting/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Global New Product Launches: Recent Success Trend Unflattering?</title>
		<link>http://www.tapanray.in/global-new-product-launches-recent-success-trend-unflattering/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=global-new-product-launches-recent-success-trend-unflattering</link>
		<comments>http://www.tapanray.in/global-new-product-launches-recent-success-trend-unflattering/#comments</comments>
		<pubDate>Mon, 24 Mar 2014 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[10]]></category>
		<category><![CDATA[2006]]></category>
		<category><![CDATA[2007]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[blockbuster]]></category>
		<category><![CDATA[FirstWord]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Januvia]]></category>
		<category><![CDATA[launches]]></category>
		<category><![CDATA[McKinsey]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[trend]]></category>
		<category><![CDATA[unflattering]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5132</guid>
		<description><![CDATA[New products are the lifeblood for any company, including the pharmaceutical players. Business performance and sustainable growth of the pharmaceutical industry, as a whole depend on quality of R&#38;D output in terms of &#8216;New Molecules&#8217;, followed by successful development and &#8230; <a href="http://www.tapanray.in/global-new-product-launches-recent-success-trend-unflattering/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/global-new-product-launches-recent-success-trend-unflattering/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
